Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05075564 · ClinicalTrials.gov registry record · Phase 1

A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors

A Phase 1 study of Advanced Solid Tumor, sponsored by Elpiscience Biopharma.

Completed
Registry status
Phase 1
Development phase
8
Enrollment target
7
Study locations

NCT05075564 is a Phase 1 study of Advanced Solid Tumor that has completed, run by Elpiscience Biopharma. The registered enrollment target is 8 participants, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (96% lower). The trial reports 7 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05075564, a Phase 1 study of Advanced Solid Tumor, has completed, sponsored by Elpiscience Biopharma.

COMPLETED
Registry status
Phase 1
Development phase
8 participants
Enrollment target
7
Study locations

Study Summary

The purpose of this first-in-human, open-label, multicenter, non-randomized study is to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary clinical activity of ES002023 in patients with advanced solid tumors that are relapsed or refractory to standard therapies.

Conditions Studied

Advanced Solid Tumor

Interventions

  • DRUG Part 1 ES002023
  • DRUG Part 2 ES002023

Study Locations (7)

Arizona

  • HonorHealth - Scottsdale

Arkansas

  • Fayetteville Oncology - Fayetteville

California

  • UCLA - Los Angeles

Florida

  • Sarah Cannon Research Institute - Orlando

New Jersey

  • Cancer Institute of New Jersey - New Brunswick

Texas

  • NEXT Austin - Austin

Virginia

  • NEXT Virginia - Fairfax

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2021-12-23
Est. Completion 2022-10-13
Phase Phase 1

Sponsor

Elpiscience Biopharma

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05075564

The ClinicalTrials.gov registry entry for NCT05075564 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (96% lower). The listed sponsor is Elpiscience Biopharma, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Part 1 ES002023 is the first listed.

NCT05075564 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Arizona, Arkansas, California.

Frequently Asked Questions

What is clinical trial NCT05075564 about?

NCT05075564 is a clinical study titled "A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors". The purpose of this first-in-human, open-label, multicenter, non-randomized study is to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary clinical activity of ES002023 in patients with advanced solid tumors that are relapsed or refractory to standard ther...

What is the current status of trial NCT05075564?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2021-12-23. Estimated completion is 2022-10-13.

What conditions does trial NCT05075564 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT05075564?

The interventions under investigation include: Part 1 ES002023 (DRUG), Part 2 ES002023 (DRUG).

Who is sponsoring clinical trial NCT05075564?

This trial is sponsored by Elpiscience Biopharma, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05075564 being conducted?

This trial has 7 study locations across Arizona, Arkansas, California, Florida, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.